Scharre DW, Shiovitz, T, Zhu Y, Amantniek J.  One-week Dose Titration Schedule for Extended-Release Galantamine in Patients With Mild-Moderate Alzheimer’s Disease. Submitted, 2007

Harrigan EP et al (Shiovitz, TM co-author). A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, in the Absence and Presence of Metabolic Inhibition.      J Clin Psychopharmacol 24:1, 62-69, 2004

Potkin SG, Shiovitz TM, Wolfgang,CD. Safety and Efficacy of 2 Iloperidone Dose Titration Schedules for the Treatment of Schizophrenia: A Haloperidol-Controlled Study. Submitted, 2007

Jhee SS et al (Shiovitz, TM co-author). First Clinical Evaluation of Ganstigmine in Patients with Probable Alzheimer’s Disease. Clin Neuropharmacol. 2003; 26(3) 164-169

Schneider LS et al (Shiovitz TM co-author) An Eight-Week, Multicenter, Parallel-group, Double-Blind, Placebo-controlled Study of Sertraline in Elderly Outpatients with Major Depression.  Am J Psychiatry 160:7, 1277-1285, July 2003

Sramek JJ, Cutler NR, Shiovitz, TM.    Short-term The Effect of Antipsychotics on Plasma Lipids.  Letter. J Clin Psychopharmacol 23(6):679-680, 2003  

Jhee SS, Kim E, Shiovitz T et al.  Single dose escalation study of PPI-1019, a Beta-Amyloid Aggregation Inhibitor. Poster. NCDEU, Boca Raton, FL      May 2003

Miceli JJ, Shiovitz TM, Swift RH, Anziano RJ.  Effects of Oral Ziprasidone and Haloperidol on QTc at Clinical and High Doses. Poster. Presented International Conference on Schizophrenia Research, April, 2003

Jhee SS (Shiovitz TM co-author). Multiple-dose Safety and Tolerability of  LY 450108 and LY451395 in Patient’s with Probable Alzheimer’s Disease. Presented (Dr Jhee), Society for Neuroscience, Orlando, November, 2002

Frackiewicz EJ, Shiovitz TM, Jhee SS. Ethnicity in Drug Development and Therapeutics.  London, Greenwich Medical Media, 2002. Book

Jhee, SS et al (Shiovitz TM co-author). LY 451395 Cerebrospinal Fluid Phamacokinetics in Healthy Human Subjects. J Clin Pharmacol 2002: 42 (9), 1067

Shiovitz T, Monici P, Pietra C, Fabbri L, Piccinno A, Jhee SS, Zarotsky V, Tan E. A Double-Blind, Placebo-Controlled Evaluation of the Safety and Tolerability of Increasing Doses of CHF 2819.01 (Ganstigmine) in Patients With Probable Alzheimer’s Disease. 7^th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva,  April, 2002.

Hossain M, Jhee SS, Shiovitz TM, et al. Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer’s Type. Clin Pharmacokinet 2002: 41(3) 225-234

Shiovitz, TM, et al. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY 36-1677 (IL-4 Selective Agonist) in Patients with Multiple Sclerosis.  poster, CINP 2002 Congress, Montreal, Canada, June, 2002.

Jhee SS, Shiovitz TM, et al. Safety and Tolerability of Serial Cerebrospinal Fluid (CSF) Collections During PK/PD Studies: 5 Years Experience – Abstract, presented 2002.

Frackiewicz EJ, Jhee SS, Shiovitz T, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler, NR Brasofensine Treatment for Parkinson’s Disease in Combination with Levodopa/Carbidopa. Ann Pharmacother 2002 February, Volume 36.

Jhee SS, Shiovitz, T, Hartman, RD, Messina, J, Cutler NR, Anand, R, Sramek, J. Centrally Acting Antiemetics Mitigate Nausea And Vomiting in AD Patients Receiving Rivastigmine. Clinical Neuropharmacology, Accepted 2002

Miceli, JJ, Anziano RJ, Swift RH, Shiovitz, TM. IM Ziprasidone and IM Haloperidol have comparable effects on QT_c at Cmax.                                                                         Poster,  American Psychiatric Association, Philadelphia, May 2002

Jhee SS, Shiovitz TM, et al. A Double-Blind, Placebo-Controlled Pharmacokinetic (PK), Pharmacodynamic (PD) and Safety of Celecoxib Treatment for Four Weeks in Patients with Alzheimer’s Disease (AD) – Abstract

Salazar DE et al (Shiovitz TM co-author). Pharmacokinetics and Tolerability of Buspirone during oral Administration in Children and Adolescents with Anxiety Disorder and Normal Healthy Adults. J Clin Pharmacol December, 2001;41:1351-1358.

Jhee, SS, Shiovitz, TM, Crawford, AW, Cutler, NR.  Clinical Pharmacokinetics of the Triptan Anti-Migraine Agents:  A Comparative Review. Clin Pharmacokin. February 2001.

Jhee, SS, Shiovitz, TM, Crawford, A, Cutler, NR, “B-Amyloid Therapies in Alzheimer’s Disease.”  Exp. Opin. Invest. Drugs (2001)10(4):593-605.

Frackiewicz, E, Shiovitz, TM, “Evaluation and Management of Premenstrual Syndrome and Premenstrual Dysphoric Disorder,” J Am Pharm Assoc 2001 May-Jun; 41(3):437-47.

Jhee, SS, PharmD, Shiovitz, TM, MD, et al. GV196771 in the CSF of Healthy Subjects Following 300 mg Oral Dose Administered Once Daily for 7 Days. poster, Am Soc Clin Pharmacol and Therapeutics, March 2001.

Pande, AC et al (Shiovitz, TM co-author). Placebo-Controlled Study of Gabapentin Treatment of Panic Disorder. J Clin Psychopharmacol 2000 Aug; 20(4):467-71.

A Meta Analysis of Clinical Safety Data from Controlled Monotherapy Trials of Lamotrigine in Depression. Ascher J, et al (Shiovitz TM co-author) Presented at American College of Neuropsychopharmacology, December 1999.

Sramek JJ, Anand R, Schran HF, Hourani J, Barto S, Wardle TS, Shiovitz, TM, Cutler NR. A Bioequivalence Study of Brand and Generic Clozapine in Patients with Schizophrenia: Pharmacokinetic and Safety Findings. ClinDrugInvest 17(1): 51-58, 1999.

Cutler NR, M.D.; Friday G, M.D.; Haskell L, M.D.; Jhee SS, Pharm.D.; Knuttsson M, M.S.; Martin T, M.A.; Ohlman S, M.D., Ph.D.; Shiovitz TM, M.D.; Sramek JJ, Pharm.D. NXX-066 in Alzheimer Patients: A Bridging Study. Abstract.  American Association of Geriatric Psychiatry New Orleans, Louisiana, March 16, 1999.

Apter J, et al (Shiovitz, TM co-author) Lamotrigine: Evidence for Antidepressant Activity in Bipolar Disorder: Abstract.  Presented at American College of Neuropsychopharmacol., December 1998.

Shiovitz, TM, et al: “The Safety and Tolerability of Sertindole in Elderly Patients with Dementia,” poster, American Association of Geriatric Psychiatry, Orlando, Florida, February .1997.

Cutler, NR et al, (Shiovitz TM. co-author). A Bridging Study of Once-Daily Iloperidone in Schizophrenic Patients – Poster 1996

Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, Kurtz NM, Cutler NR. Cholinergic rebound and rapid onset psychosis following abrupt Clozapine withdrawal.  Schizophr Bull. 1996;22(4):591-5.

[Home] [For Patients] [Sponsor Overview] [Experience] [Performance] [Facilities] [Staff] [Contact Us]